Rennova Health announced an agreement between its subsidiary Advanced Molecular Services Group and Certainty Health.
Rennova Health (NASDAQ:RNVA; NASDAQ:RNVAZ) announced an agreement between its subsidiary Advanced Molecular Services Group and Certainty Health to develop smartphone tools for patients to “assess” their genetic background in treatment.
As quoted in the press release:
“We look forward to working with Rennova Health to expand a mobile precision medicine platform to immediately address the unmet needs of patients and their caregivers for relevant molecular information impacting psychiatry today,” stated Dr. Chris Yoo, President and COO of Certainty Health. “Rennova’s incredibly rich and growing databases of pharmacogenomic drug metabolism data represents over a decade of real-world diagnostic results for multiple diseases and together with Rennova, we will democratize access to this knowledge for the benefit of patients.”
Under the terms of the agreement, Rennova will market consumer-facing genetic tests developed by its AMS Group using the Certainty Health brand. The first products to be offered through the mobile platform will include tests that can determine how an individual might respond to a number of pharmaceutical drugs used to treat psychiatric disorders. In the U.S. according to NAMI, the National Alliance on Mental Illness, 43.8 million people are being treated for psychiatric issues and an estimated 66% more people go untreated, according to the World Health Organization. The collaboration will deliver test results for these patients, physicians, and other stakeholders in the circle of care team to increase the chances that the right drug will be chosen for the right patient in the right amount.